Full Breakdown
Walmart Reports Slowest U.S. Same-Store Sales Growth in Six Years Amid Pharmacy Price Caps and Fuel-Cost Pressure
8/20/2026, 7:54:07 PM
Core Findings
- U.S. comparable sales rose 2.6% in the quarter ended July 31, the smallest increase since 2020.
- Adjusted earnings per share reached $0.81, beating the consensus estimate of $0.74, while revenue grew about 5.9% to roughly $187.9 billion.
- The company lifted its full-year sales outlook to 4-5% growth and adjusted EPS to $2.80-$2.87, yet shares fell 6-9% after the release.
Background & Context
- New federal negotiations on Medicare drug pricing introduced “maximum fair price” caps, lowering pharmacy margins and creating a 0.8-percentage-point drag on U.S. comparable sales.
- Gasoline prices above $4 per gallon in July heightened household cost pressure, a factor the company cites for consumer trade-offs.
- Walmart began receiving $2.9 billion in tariff refunds from a 2022 Supreme Court ruling; less than $100 million remains pending.
Data & Statistics
- Revenue: $187.94 billion (FactSet consensus $186.62 billion).
- U.S. comparable sales: 2.6% YoY; 3.4% when the health-and-wellness category is excluded.
- E-commerce growth: 23-24% globally and in the United States.
- Tariff-refund benefit: added 96 basis points to gross margin; incremental fuel-cost headwinds projected at $2 billion.
- Net income: $6.37 billion; adjusted EPS $0.81.
Official Statements & Responses
- CFO John David Rainey said the business remains strong and that the tariff refunds will be used to lower consumer prices, with the impact expected in the third quarter.
- Rainey warned that higher fuel costs will add just over $2 billion of incremental expenses for the year.
- CEO John Furner highlighted continued market-share gains among households earning over $100,000 and pointed to growth in e-commerce, advertising and Walmart+ membership as new profit engines.
- The company noted that the pharmacy-price caps accounted for an 80-basis-point headwind to comparable sales.
Why It Matters
- Walmart’s same-store sales metric is a widely watched barometer of U.S. consumer health; the slowdown signals that even value-oriented shoppers are feeling budget pressure.
- Federal drug-price policy can directly suppress retail revenue, a factor analysts will monitor for future quarters.
Conflicting Reports & Gaps
- Revenue figure: reported as $187.94 billion (AP, CNBC) and $187.9 billion (BigGo, CNBC TV18); the discrepancy reflects rounding differences.
- Full-year guidance: most sources cite a 4-5% sales growth range, while earlier guidance was 3.5-4.5%; the exact upper bound varies between 4.5% and 5% across outlets.
Verbatim Quotes
What’s Next
- Walmart projects third-quarter net-sales growth of 3-3.75% (constant currency) and adjusted EPS of $0.62-$0.64, noting a >100-basis-point headwind from the timing shift of Flipkart’s “Big Billion Days” promotion.
- The retailer will continue applying remaining tariff refunds to price reductions and expects the fuel-cost impact to remain around $2 billion for the fiscal year.
